Utilization and Impact of Extended-Interval Dosing of Immunotherapy on Outcomes in Patients with Locally Advanced NSCLC
This study will evaluate the utilization and dosing of durvalumab and associations with treatment outcomes among patients with unresectable stage III non-small cell lung cancer in an integrated health care system.
Investigator: Sakoda, Lori
Funder: AstraZeneca PLC
